Sign In
Buy PGEN
$6.27
+0.330 (+5.56%)
At Close: Jul 31, 2026
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
08:23am, Sunday, 07'th Sep 2025
Investors in search of stocks that can produce dramatic gains in a short time frame will want to turn their heads toward the healthcare sector. A handful of stocks in the space more than doubled in pr
Precigen Announces Up to $125 Million Non-Dilutive Financing
07:00am, Wednesday, 03'rd Sep 2025
$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and o
Precigen, Inc. - Special Call
01:55pm, Tuesday, 02'nd Sep 2025
Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwr
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
12:06pm, Monday, 25'th Aug 2025
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
08:05am, Monday, 25'th Aug 2025
GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of p
Undercovered Dozen: Precigen, ONEOK, Bitmine And More
10:43am, Friday, 22'nd Aug 2025
This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement
Precigen price target raised to $8 from $6 at Citizens JMP
05:38am, Tuesday, 19'th Aug 2025
Citizens JMP raised the firm's price target on Precigen to $8 from $6 and keeps an Outperform rating on the shares. Precigen discussed the approval of PAPZIMEOS for the treatment of respiratory papill
Precigen: This Billion-Dollar Approval Is Still Undervalued
03:15pm, Friday, 15'th Aug 2025
PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, t
Why Is Precigen Stock Surging On Friday?
09:48am, Friday, 15'th Aug 2025
On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).
US FDA approves Precigen's immunotherapy for rare respiratory disease
07:18am, Friday, 15'th Aug 2025
The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FD
Precigen: August Is Pivotal For This Biotech Innovator
05:58pm, Monday, 07'th Jul 2025
Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Rec
Precigen Reports First Quarter 2025 Financial Results and Business Updates
04:05pm, Wednesday, 14'th May 2025
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA targ
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
08:05am, Wednesday, 16'th Apr 2025
– International event will raise awareness and bring together RRP patients , caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilita
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
07:47pm, Wednesday, 19'th Mar 2025
Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CC
